Dermatology

Additional validation of such improvement thresholds using unblinded trial data may be necessary to allow for more evidence of their utility in clinical research and practice.

Additional research on this form of moisturizer and other ingredients for acne with larger sample sizes may be needed to verify efficacy for acne vulgaris.

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

These findings on reasons for attendance and other trends highlight the importance of mental health care among alopecia patients.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

The FDA set its target action date for October, with this sNDA being supported by two phase 1 safety studies on AK patients.

In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.

This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

January’s Dermatology Month in Review features 2 major FDA decisions, positive results on a new assessment tool, an evaluation of climate change’s impact on eczema, and more.

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.

This analysis of current testing patterns in the US suggests a need for future studies to explore the rationale used to determine such testing decisions.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

Vitiligo was significantly associated with an increased risk of bacteremia, cellulitis, and herpes zoster and was more common among those with female sex, Black compared to White race, Hispanic ethnicity, hepatitis C infection, and tobacco use.

These data represent a significant step toward finding a causal connection for drug-induced alopecia, though further controlled studies may be necessary to isolate certain variables.

These data were the results of the secondary analysis of the Ritux 3 study, as the treatment’s short-term efficacy and safety had been confirmed previously.

This study contributes to existing climate change data by exploring climatic hazards and their relationship with atopic dermatitis, in addition to highlighting research gaps and future predictions.

This study and its development of the Prurigo Control Test represents the first of its kind to assess chronic prurigo disease control.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’